Japanese company profile · 7774
Japan Tissue Engineering Co., Ltd.
English company name recorded in Japan's EDINET filer data.
Original Japanese company name: 株式会社ジャパン・ティッシュエンジニアリング
Name follows the English name recorded in EDINET filer data. English company name source
FY2025 · fiscal year ended March 2026Latest filing date: 2026-06-18What does this company do?
What does this company do?
In its FY2025 public filing, Japan Tissue Engineering Co., Ltd. reports Regenerative medicine, Regenerative Medicine Trust, Labsite. The page shows business-level revenue and profit where the source disclosures support comparison.
Japan Tissue Engineering Co., Ltd.'s largest reported business by revenue in FY2025 was Regenerative medicine.
The business with the highest reported segment profit in FY2025 was Regenerative Medicine Trust.
FY2025 · fiscal year ended March 2026 · View original filing ↗ The source document may be in Japanese.
Reported company-wide figures
- Company revenue
- ¥2.18B ↗ FY2025 · fiscal year ended March 2026
- Operating profit
- −¥549.45M ↗ FY2025 · fiscal year ended March 2026
- Comparable margin
- -25.2% ↗ FY2025 · fiscal year ended March 2026
JGAAP · Parent-only
Company profile
Identity
- Securities code
- 7774
- EDINET code
- E02357
- Corporate number
- 4180301011063
- Listing status
- Listed
- Industry (EDINET filer classification)
- Precision instruments
Location and fiscal year
- Headquarters
- 愛知県蒲郡市 · As filed in Japanese
- Fiscal year end
- 3month
- Latest fiscal year
- FY2025
- Accounting standard
- JGAAP
- P16 data snapshot
- 2026-11-07
Company size
- Employees (non-consolidated)
- 200 people (FY2025)
- Capital stock
- JPY 4.0 billion (FY2025)
Official information
- Latest annual securities report
- Latest annual securities report Opens in a new tab
Public information is organized and presented by P16. EDINET filer list (2026-11-07) Opens in a new tab · EDINET PDL 1.0 terms Opens in a new tab
Business structure
How does it make money?
Revenue leader and profit leader
RevenueRegenerative medicine
ProfitRegenerative Medicine Trust
| Business | Sales | Share of company sales | Operating profit | Margin |
|---|---|---|---|---|
| Regenerative medicine | ¥1.35B ↗ | — | ¥78.3M ↗ | 5.8% |
| Regenerative Medicine Trust | ¥546.37M ↗ | — | ¥327.44M ↗ | 59.9% |
| Labsite | ¥281.88M ↗ | — | ¥52.77M ↗ | 18.7% |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended March 2026. Revenue and profit are shown only where the filing and data support a comparison. “—” means a comparable amount was not disclosed. We compare sales to outside customers for each business and the company as a whole, using the same filing, fiscal year and scope. Reported business sales may include sales between businesses. We leave the share blank when the figures cannot be matched.
Company revenue
Company-wide trend
Company revenue
JGAAP · Parent-only- FY2021
83.7 ¥2.1B - FY2022
80.8 ¥2.03B - FY2023
100.0 ¥2.51B - FY2024
97.7 ¥2.46B - FY2025
86.8 ¥2.18B
Company operating profit
JGAAP · Parent-only- FY2021
68.4 −¥498.18M - FY2022
100.0 −¥728.12M - FY2023
19.8 ¥144.51M - FY2024
32.7 −¥238.31M - FY2025
75.5 −¥549.45M
Only reported years are shown. Missing years are left blank; accounting standards and scopes are kept in separate series.
What has changed?
Businesses reported in earlier filings
Reporting labels alone do not prove that a business started, ended, merged, or changed its identity.
- 研究開発支援事業 (Original Japanese label)FY 2021–FY 2024 · Source
What is growing?
What is growing?
No comparable reported revenue growth is available.
What has changed?
What has changed?
A five-year business-mix comparison is not shown because the available filings do not provide five comparable years on the same basis.
Source
Company profile
These scores summarize company characteristics using public filings. Comparison groups vary by measure. Higher is not always better.
- GrowthPosition among all companies with available values in the fixed reference data.FY2021→FY2025
19 - ProfitabilityPosition among all companies with available values in the fixed reference data.FY2025
2 - Business concentration—No comparable data
- Business change—No comparable data
- Cash generation—No comparable data
- Growth persistencePeer-position scoreFY2021→FY2022, FY2022→FY2023, FY2023→FY2024, FY2024→FY2025
5
Source
Public filing
FY2025 · fiscal year ended March 2026
The source document may be in Japanese.
Filing ID: S100YDBW
View original filing ↗Original Japanese label
- Original Japanese label
- 研究開発支援事業